Sanofi stock gains on FDA approval for updated Covid shots
Published on 08/28/2026 at 17:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sanofi stock gained a new catalyst on August 27, 2026, after U.S. regulators approved updated Covid vaccines for the 2026-27 season, including the Novavax-Sanofi shot for eligible groups. Shares in Sanofi (FR0000127771) last traded at $44.84 in the U.S. market view, with a market value of $108.71 billion.
FDA approval adds a fresh angle
The approval covers vaccines aimed at the XFG variant, and the U.S. Food and Drug Administration cleared shipment plans ahead of the respiratory-virus season. A Reuters report on August 27, 2026, said Moderna, Novavax-Sanofi and Pfizer-BioNTech all received the updated authorization.
That matters because Sanofi's vaccine franchise now has a clearly dated commercialization trigger, while the stock itself remains close to a 52-week range of $40.89 to $52.68. The latest market view also shows a 200-day moving average of $44.83, which puts the shares almost exactly on that longer trend line.
Revenue still sets the frame
MarketBeat's August 28, 2026 analyst snapshot says Sanofi reported second-quarter 2026 earnings of $2.41 per share on revenue of $13.36 billion. It also notes that revenue rose 16.0% from the same quarter a year earlier, while the consensus recommendation from 15 brokerages stands at Hold.
The same update puts the average 12-month price objective at $49.50 and the implied valuation at a price-to-earnings ratio of 23.48. For investors, the combination of $13.36 billion in quarterly sales and a 16.0% year-over-year rise gives the vaccine headline more context than the share price alone.
Pipeline and product
Sanofi's vaccine business is the immediate focal point, but its broader portfolio still matters to the equity story. The company is also linked to a key immunology product that was described in recent coverage as reaching $6.0 billion in global net sales in the second quarter of 2026, up 38% year over year.
That product mix helps explain why the shares can react to both regulatory news and earnings data. The market is still weighing whether the latest vaccine approval simply adds seasonal support or reinforces a wider growth case.
Nuvaxovid moves next
Nuvaxovid is the product most directly tied to the new authorization, with the shot positioned for adults and certain high-risk groups in the coming season. The commercial detail matters because the FDA decision turns a regulatory headline into a nearer-term sales opportunity.
As of August 27, 2026, the U.S.-listed view showed Sanofi at $44.84, with the stock sitting below the $49.50 analyst average target and close to the 200-day moving average of $44.83.
Fact box
Company: Sanofi
ISIN: FR0000127771
Ticker: SNY
Exchange: Nasdaq
Price (as of August 27, 2026, 21:59 p.m. ET): $44.84 USD
Market cap: $108.71 billion (as of August 28, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: Nasdaq 100
More on Sanofi stock
Sanofi stock remains tied to the balance between vaccine execution, immunology sales and analyst expectations. The next quarter will show whether the FDA approval is enough to improve sentiment beyond the current Hold consensus.
